Galena Biopharma (NASDAQ:GALE) shareholders have had a rough 2014 so far, with the stock dipping over 50% from its highs just north of $7 to a recent share price of just over $3. The stock has been plagued by rumors and allegations of share price manipulation and a variety of other issues. But let's leave the rumors aside and focus on the fundamentals and the pipeline, the actual business behind the share price.

So is it time to buy the stock?

In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson answer.

Even if it returns to its previous highs, Galena may have serious trouble keeping up with this top stock
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.